Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × fedratinib × Other hematologic neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 9 venetoclax 7 Rituximab 7 Daunorubicin 7 nilotinib 6 blinatumomab 5 Bendamustine Hydrochloride 5 Azacitidine 5 bosutinib 4 pegaspargase 3 obinutuzumab 3 asciminib 3 acalabrutinib 3 Mitoxantrone 3 Methotrexate 3 Imatinib Mesylate 3 Etoposide 3 Cyclophosphamide 3 zanubrutinib 2 talquetamab 2 revumenib 2 pirtobrutinib 2 merphos 2 ivosidenib 2 idelalisib 2 ibrutinib 2 fludarabine 2 avapritinib 2 asparaginase erwinia chrysanthemi recombinant 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01437787 2025-03-05

JAKARTA

Bristol-Myers Squibb

Phase 3 Completed

289 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡